AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21381963 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 42
Study 21381963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 42
Study 18617832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive coaching intervention
Number of subjects: 0
Study 18617832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 16585434 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99
Study 16585434 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 99
Study 16585434 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 99
Study 16585434 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 99
Study 12855628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at P6
Number of subjects: 80
Study 12855628 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture at P6
Number of subjects: 80
Study 11196233 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Active Concept therapy
Number of subjects: 68
Study 11196233 — intervention group
Group type: COMPARATOR
Intervention: Edgewise therapy (Control)
Number of subjects: 68
Study 8769679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment (continuous 17‐beta‐estradiol 2 mg and norethisterone acetate 1 mg per day)
Number of subjects: 80
Study 8769679 — intervention group
Group type: COMPARATOR
Intervention: Transdermal therapy (patches delivering continuous 17‐beta‐estradiol 0.05 mg/day with sequential oral medroxyprogesterone acetate 10 mg/day for 12 days/cycle)
Number of subjects: 80
Study 1605900 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 2 mg
Number of subjects: 29
Study 1605900 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 29
Study 1605900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3884627 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus insulin (1 g + 1.5 U/kg bw X h) before and after ischaemic heart arrest
Number of subjects: 36
Study 3884627 — intervention group
Group type: COMPARATOR
Intervention: Control group received glucose without insulin
Number of subjects: 36
Study 30285187 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2)
Number of subjects: 960
Study 30285187 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2) or 1 × 105 cfu/g (CB3)
Number of subjects: 960
Study 30285187 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with C. butyricum
Number of subjects: 960
Study 30285187 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 960
Study 29492637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplement (7.5 g of insoluble fibre per serving, twice daily for 2 years)
Number of subjects: 180
Study 29492637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.8 g of insoluble fibre per serving, twice daily for 2 years)
Number of subjects: 180
Study 29492637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplement
Number of subjects: 180
Study 29492637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 27585414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil 0.25 μg/kg/min (PRe‐0.25)
Number of subjects: 80
Study 27585414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil 0.125 μg/kg/min (PRe‐0.125)
Number of subjects: 80
Study 27585414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/66% nitrous oxide (PN)
Number of subjects: 80
Study 27585414 — intervention group
Group type: COMPARATOR
Intervention: Propofol/saline solution (PS)
Number of subjects: 80
Study 25312556 — intervention group
Group type: EXPERIMENTAL
Intervention: MumsQuit (Internet-based Smoking Cessation Intervention)
Number of subjects: 13
Study 22393129 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant evidence (5-year survival increased from 68% to 99%)
Number of subjects: 412
Study 22393129 — intervention group
Group type: COMPARATOR
Intervention: Relevant evidence (cancer mortality reduced from 2 to 1.6 in 1000 persons)
Number of subjects: 412
Study 22393129 — intervention group
Group type: EXPERIMENTAL
Intervention: General knowledge questions about screening statistics
Number of subjects: 412
Study 22393129 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding more cases of cancer in screened populations
Number of subjects: 412
Study 20146800 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Number of subjects: 14
Study 20146800 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study 17663618 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy
Number of subjects: 162
Study 17663618 — intervention group
Group type: COMPARATOR
Intervention: Group interpersonal psychotherapy
Number of subjects: 162
Study 16118760 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) combined with physiotherapy
Number of subjects: 55
Study 16118760 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone (PT group)
Number of subjects: 55
Study 12704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline gauze (F)
Number of subjects: 0
Study 12704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane (B)
Number of subjects: 0
Study 12704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressing (O)
Number of subjects: 0
Study 12704925 — intervention group
Group type: COMPARATOR
Intervention: Normal mirror-sided skin
Number of subjects: 0
Study 12704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutometer (Courage and Khazaka)
Number of subjects: 0
Study 10400143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 12
Study 10400143 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 8614572 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 8
Study 8614572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1975277 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg qhs
Number of subjects: 25
Study 1975277 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg qhs
Number of subjects: 25
Study 1975277 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg qhs
Number of subjects: 25
Study 375376 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)15 methyl prostaglandin E2 (free acid) at doses of 80, 140, 200, and 400 micrograms
Number of subjects: 11
Study 375376 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)15 methyl prostaglandin E2 (methylester) at doses of 80, 140, and 200 micrograms
Number of subjects: 11
Study 375376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 80 micrograms methyl ester and 1.5 mg atropine sulphate
Number of subjects: 11
Study 375376 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 11
Study 31189680 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroSAFE RALP
Number of subjects: 50
Study 31189680 — intervention group
Group type: COMPARATOR
Intervention: Standard RALP
Number of subjects: 50
Study 27528118 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy (experimental arm)
Number of subjects: 200
Study 27528118 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy (control arm)
Number of subjects: 200
Study 25975643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention (exercise, education, relaxation sessions, 6 to 8 sessions bi- to triweekly)
Number of subjects: 61
Study 25975643 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 61
Study 25975643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention
Number of subjects: 61
Study 25975643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention (for those undergoing neoadjuvant therapy)
Number of subjects: 61
Study 25975643 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group, for those undergoing neoadjuvant therapy)
Number of subjects: 61
Study 23971512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 A's smoking cessation intervention delivered by trained midwives in 10 intervention clinics
Number of subjects: 20
Study 23971512 — intervention group
Group type: COMPARATOR
Intervention: Standard in-service activities in 10 control clinics
Number of subjects: 20
Study 23971512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 A's smoking cessation intervention
Number of subjects: 20
Study 23971512 — intervention group
Group type: COMPARATOR
Intervention: Standard in-service activities
Number of subjects: 20
Study 21721962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Promotion (AP) intervention
Number of subjects: 434
Study 21721962 — intervention group
Group type: COMPARATOR
Intervention: Cancer control condition
Number of subjects: 434
Study 19545384 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Perception of Study Medication (PPSM) questionnaire
Number of subjects: 879
Study 19545384 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSM-Global and PPSM-Pain factors
Number of subjects: 879
Study 19545384 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSM
Number of subjects: 879
Study 16677266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 microg.kg(‐1) intravenously)
Number of subjects: 120
Study 16677266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 120
Study 15100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (24 g/day of white wine)
Number of subjects: 18
Study 15100619 — intervention group
Group type: COMPARATOR
Intervention: White grape juice (control)
Number of subjects: 18
Study 11778969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST) with infusional chemotherapy (IC) using VAMP/C-VAMP followed by autologous transplantation and interferon maintenance
Number of subjects: 251
Study 11778969 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy consolidation
Number of subjects: 251
Study 11778969 — intervention group
Group type: COMPARATOR
Intervention: Cox analysis variables
Number of subjects: 251
Study 9314107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal movement
Number of subjects: 82
Study 9314107 — intervention group
Group type: COMPARATOR
Intervention: Control measurement by a blinded examiner
Number of subjects: 82
Study 8419199 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 2 to 6 of the menstrual cycle
Number of subjects: 30
Study 8419199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil 400 mg on days 3 to 12 of the menstrual cycle
Number of subjects: 30
Study 8419199 — intervention group
Group type: COMPARATOR
Intervention: Normal ovulatory cycles (Control)
Number of subjects: 30
Study 2868873 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular elemental diet (diet 1)
Number of subjects: 26
Study 2868873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular elemental diet (diet 2)
Number of subjects: 26
Study 30500336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered lidocaine gel 2% 20mL intravaginally 15-30min before procedure initiation
Number of subjects: 72
Study 30500336 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% 12mL paracervical block immediately prior to dilator placement
Number of subjects: 72
Study 30500336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered lidocaine gel
Number of subjects: 72
Study 30500336 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine paracervical block
Number of subjects: 72
Study 30367608 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated feedback about ambulatory assessed early warning signs
Number of subjects: 120
Study 30367608 — intervention group
Group type: COMPARATOR
Intervention: Control group without feedback
Number of subjects: 120
Study 27465818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Luo Hua Shi (TLHS) 4.8 g/day
Number of subjects: 236
Study 27465818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Luo Hua Shi (TLHS) 3.6 g/day
Number of subjects: 236
Study 27465818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 24576156 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (IFN B 1B)
Number of subjects: 19
Study 24576156 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab (NTZ)
Number of subjects: 19
Study 22999634 — intervention group
Group type: COMPARATOR
Intervention: Prompt laser treatment
Number of subjects: 361
Study 22999634 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred laser treatment
Number of subjects: 361
Study 20478865 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Smoking (PS) exposure for 1 hour
Number of subjects: 17
Study 17629158 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of cefaclor twice daily for five to seven days
Number of subjects: 63
Study 17629158 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of cefaclor three times daily for five to seven days
Number of subjects: 63
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: IL-1ra serum concentration
Number of subjects: 27
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: IL-1ra urinary excretion
Number of subjects: 27
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: sTNFR I serum concentration
Number of subjects: 27
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: sTNFR I urinary excretion
Number of subjects: 27
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: sTNFR II serum concentration
Number of subjects: 27
Study 16209246 — intervention group
Group type: COMPARATOR
Intervention: sTNFR II urinary excretion
Number of subjects: 27
Study 16209246 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-1ra serum concentration
Number of subjects: 27
Study 16209246 — intervention group
Group type: EXPERIMENTAL
Intervention: uIL-1ra urinary excretion
Number of subjects: 27
Study 11931374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen adsorption treatment (4 treatments for healthy subjects, 144 treatments for patients)
Number of subjects: 18
Study 11931374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen adsorption treatment
Number of subjects: 18
Study 10408327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program for 9 weeks
Number of subjects: 30
Study 10408327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study 8749600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 150
Study 8749600 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only pill (POP)
Number of subjects: 150
Study 8749600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2390880 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg daily
Number of subjects: 345
Study 2390880 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily
Number of subjects: 345
Study 2390880 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily
Number of subjects: 345
Study 2390880 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg daily
Number of subjects: 345
Study 2390880 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (control)
Number of subjects: 345
Study 6117302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rimiterol (1050 microgram cumulative dose over 90 min)
Number of subjects: 12
Study 6117302 — intervention group
Group type: COMPARATOR
Intervention: Aerosol rimiterol
Number of subjects: 12
Study 6117302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rimiterol
Number of subjects: 12
Study 31557763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy
Number of subjects: 7487
Study 31557763 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus either clopidogrel or ticagrelor for 12 months followed by 12-month aspirin monotherapy
Number of subjects: 7487
Study 28139362 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation (RNI) - 50 Gy
Number of subjects: 2106
Study 28139362 — intervention group
Group type: COMPARATOR
Intervention: Completion axillary lymph node dissection (cALND) - standard treatment
Number of subjects: 2106
Study 25884949 — intervention group
Group type: EXPERIMENTAL
Intervention: DXSCNP classifier
Number of subjects: 169
Study 25884949 — intervention group
Group type: COMPARATOR
Intervention: DXCLINICAL2 classifier
Number of subjects: 169
Study 23430349 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap (LF)
Number of subjects: 295
Study 23430349 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF)
Number of subjects: 295
Study 23430349 — intervention group
Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 295
Study 22527920 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal cooler
Number of subjects: 100
Study 22527920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cooler)
Number of subjects: 100
Study 19953915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 10 mg IV (Group D)
Number of subjects: 30
Study 19953915 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 120 mg IV (Group M)
Number of subjects: 30
Study 19953915 — intervention group
Group type: COMPARATOR
Intervention: Normal saline, 10 ml IV (Group S)
Number of subjects: 30
Study 19953915 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group D and Group M
Number of subjects: 30
Study 19953915 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group D and Group S
Number of subjects: 30
Study 17329696 — intervention group
Group type: EXPERIMENTAL
Intervention: rHEV vaccine
Number of subjects: 2000
Study 17329696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 16272454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy and adjuvant chemotherapy
Number of subjects: 0
Study 16272454 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel molecular targeted therapies (trastuzumab)
Number of subjects: 0
Study 16272454 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 0
Study 16272454 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling
Number of subjects: 0
Study 11835924 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 3987
Study 11835924 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg 3 times daily or diclofenac 75 mg twice daily
Number of subjects: 3987
Study 11835924 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 3987
Study 11835924 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (combined or individually)
Number of subjects: 3987
Study 10800498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (interferon-alpha)
Number of subjects: 0
Study 10800498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (interleukin-2)
Number of subjects: 0
Study 10800498 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies (cytotoxic chemotherapies)
Number of subjects: 0
Study 10800498 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy approaches
Number of subjects: 0
Study 7675377 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 52
Study 7675377 — intervention group
Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 52
Study 1688980 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (0.3 micrograms/kg/min infusion)
Number of subjects: 45
Study 1688980 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg bolus)
Number of subjects: 45
Study 1688980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Enoximone (same dosages as above)
Number of subjects: 45
Study 6784924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (37.5 g by 6-hour infusion)
Number of subjects: 22
Study 6784924 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 22
Study 6784924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 every 21-28 days)
Number of subjects: 22
Study 31599637 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70
Study 31599637 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 70
Study 29233720 — intervention group
Group type: EXPERIMENTAL
Intervention: Northwestern Medical Group‐ Transitional Care (NMG‐TC) care model
Number of subjects: 0
Study 29233720 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26547100 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 (pegnivacogin 1 mg/kg bolus followed by 80% reversal with anivamersen)
Number of subjects: 3232
Study 26547100 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 3232
Study 26547100 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1
Number of subjects: 3232
Study 24935230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group AB
Number of subjects: 13627
Study 24935230 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (transfusion)
Number of subjects: 13627
Study 22133650 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-sustained-release-led (Ve-led) treatment strategy
Number of subjects: 1019
Study 22133650 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-led (At-led) treatment strategy
Number of subjects: 1019
Study 20060711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564
Study 20060711 — intervention group
Group type: COMPARATOR
Intervention: No Tamoxifen
Number of subjects: 564
Study 18337008 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 517 (TRPV1 antagonist)
Number of subjects: 0